Sweden

Elypta is commercializing the world's first pan-cancer liquid biopsy platform based on metabolism. Exceptional sensitivity in all stages of cancer enables applications from screening to follow-up and response monitoring. The first application is early detection of recurring renal cell carcinoma with other urological cancers close behind.

Presenter: Karl Bergman, CEO, Elypta AB